Skip to main content
Top
Published in: Endocrine Pathology 1/2017

01-03-2017

MALAT1 Long Non-coding RNA Expression in Thyroid Tissues: Analysis by In Situ Hybridization and Real-Time PCR

Authors: Ranran Zhang, Heather Hardin, Wei Huang, Jidong Chen, Sofia Asioli, Alberto Righi, Francesca Maletta, Anna Sapino, Ricardo V. Lloyd

Published in: Endocrine Pathology | Issue 1/2017

Login to get access

Abstract

Long non-coding RNAs (lncRNAs) are important for transcription and for epigenetic or posttranscriptional regulation of gene expression and may contribute to carcinogenesis. Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), an lncRNA involved in the regulation of the cell cycle, cell proliferation, and cell migration, is known to be deregulated in multiple cancers. Here, we analyzed the expression of MALAT1 on 195 cases of benign and malignant thyroid neoplasms by using tissue microarrays for RNA in situ hybridization (ISH) and real-time PCR. MALAT1 is highly expressed in normal thyroid (NT) tissues and thyroid tumors, with increased expression during progression from NT to papillary thyroid carcinomas (PTCs) but is downregulated in poorly differentiated thyroid cancers (PDCs) and anaplastic thyroid carcinomas (ATCs) compared to NT. Induction of epithelial to mesenchymal transition (EMT) by transforming growth factor (TGF)-beta in a PTC cell line (TPC1) led to increased MALAT1 expression, supporting a role for MALAT1 in EMT in thyroid tumors. This is the first ISH study of MALAT1 expression in thyroid tissues. It also provides the first piece of evidence suggesting MALAT1 downregulation in certain thyroid malignancies. Our findings support the notion that ATCs may be molecularly distinct from low-grade thyroid malignancies and suggest that MALAT1 may function both as an oncogene and as a tumor suppressor in different types of thyroid tumors.
Literature
1.
go back to reference Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011;7(10):569–580.CrossRefPubMed Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011;7(10):569–580.CrossRefPubMed
3.
go back to reference Li X, Wu Z, Fu X, Han W. Long Noncoding RNAs: Insights from Biological Features and Functions to Diseases. Med Res Rev. 2013;33(3):517–553.CrossRefPubMed Li X, Wu Z, Fu X, Han W. Long Noncoding RNAs: Insights from Biological Features and Functions to Diseases. Med Res Rev. 2013;33(3):517–553.CrossRefPubMed
4.
go back to reference He H, Nagy R, Liyanarachchi S, Jiao H, Li W, Suster S, et al. A Susceptibility Locus for Papillary Thyroid Carcinoma on Chromosome 8q24. Cancer Res. 2009;69(2):625–631.CrossRefPubMedPubMedCentral He H, Nagy R, Liyanarachchi S, Jiao H, Li W, Suster S, et al. A Susceptibility Locus for Papillary Thyroid Carcinoma on Chromosome 8q24. Cancer Res. 2009;69(2):625–631.CrossRefPubMedPubMedCentral
5.
go back to reference He H, Li W, Liyanarachchi S, Jendrzejewski J, Srinivas M, Davuluri R V, et al. Genetic Predisposition to Papillary Thyroid Carcinoma: Involvement of FOXE1, TSHR, and a Novel lincRNA Gene, PTCSC2. J Clin Endocrinol Metab. 2015;100(1):E164–E172.CrossRefPubMed He H, Li W, Liyanarachchi S, Jendrzejewski J, Srinivas M, Davuluri R V, et al. Genetic Predisposition to Papillary Thyroid Carcinoma: Involvement of FOXE1, TSHR, and a Novel lincRNA Gene, PTCSC2. J Clin Endocrinol Metab. 2015;100(1):E164–E172.CrossRefPubMed
6.
go back to reference Jendrzejewski J, He H, Radomska HS, Li W, Tomsic J, Liyanarachchi S, et al. The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type. Proc Natl Acad Sci U S A. 2012;109(22):8646–8651.CrossRefPubMedPubMedCentral Jendrzejewski J, He H, Radomska HS, Li W, Tomsic J, Liyanarachchi S, et al. The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type. Proc Natl Acad Sci U S A. 2012;109(22):8646–8651.CrossRefPubMedPubMedCentral
7.
go back to reference Zhang R, Hardin H, Chen J, Guo Z, Lloyd R V. Non-Coding RNAs in Thyroid Cancer. Endocr Pathol. 2016;27(1):12–20.CrossRefPubMed Zhang R, Hardin H, Chen J, Guo Z, Lloyd R V. Non-Coding RNAs in Thyroid Cancer. Endocr Pathol. 2016;27(1):12–20.CrossRefPubMed
8.
go back to reference Zheng H, Wang M, Jiang L, Chu H, Hu J, Ning J, et al. BRAF-activated Long Non-coding RNA Modulates Papillary Thyroid Carcinoma Cell Proliferation through Regulating Thyroid Stimulating Hormone Receptor. Cancer Res Treat. 2015; Zheng H, Wang M, Jiang L, Chu H, Hu J, Ning J, et al. BRAF-activated Long Non-coding RNA Modulates Papillary Thyroid Carcinoma Cell Proliferation through Regulating Thyroid Stimulating Hormone Receptor. Cancer Res Treat. 2015;
9.
go back to reference Zhou Q, Chen J, Feng J, Wang J. Long noncoding RNA PVT1 modulates thyroid cancer cell proliferation by recruiting EZH2 and regulating thyroid-stimulating hormone receptor (TSHR). Tumour Biol. 2015; Zhou Q, Chen J, Feng J, Wang J. Long noncoding RNA PVT1 modulates thyroid cancer cell proliferation by recruiting EZH2 and regulating thyroid-stimulating hormone receptor (TSHR). Tumour Biol. 2015;
10.
go back to reference Ma X-Y, Wang J-H, Wang J-L, Ma CX, Wang X-C, Liu F-S. Malat1 as an evolutionarily conserved lncRNA, plays a positive role in regulating proliferation and maintaining undifferentiated status of early-stage hematopoietic cells. BMC Genomics. 2011;16(676). Ma X-Y, Wang J-H, Wang J-L, Ma CX, Wang X-C, Liu F-S. Malat1 as an evolutionarily conserved lncRNA, plays a positive role in regulating proliferation and maintaining undifferentiated status of early-stage hematopoietic cells. BMC Genomics. 2011;16(676).
11.
go back to reference Buehler D, Hardin H, Shan W, Montemayor-Garcia C, Rush PS, Asioli S, et al. Expression of epithelial-mesenchymal transition regulators SNAI2 and TWIST1 in thyroid carcinomas. Mod Pathol. 2012;26(10):54–61.PubMedPubMedCentral Buehler D, Hardin H, Shan W, Montemayor-Garcia C, Rush PS, Asioli S, et al. Expression of epithelial-mesenchymal transition regulators SNAI2 and TWIST1 in thyroid carcinomas. Mod Pathol. 2012;26(10):54–61.PubMedPubMedCentral
12.
go back to reference Guo Z, Hardin H, Montemayor-Garcia C, Asioli S, Righi A, Maletta F, et al. In Situ Hybridization Analysis of miR-146b-5p and miR-21 in Thyroid Nodules: Diagnostic Implications. Endocr Pathol. 2015;26(2):157–163.CrossRefPubMed Guo Z, Hardin H, Montemayor-Garcia C, Asioli S, Righi A, Maletta F, et al. In Situ Hybridization Analysis of miR-146b-5p and miR-21 in Thyroid Nodules: Diagnostic Implications. Endocr Pathol. 2015;26(2):157–163.CrossRefPubMed
13.
go back to reference Huang W, Eickhoff JC, Mehraein-Ghomi F, Church DR, Wilding G, Basu HS. Expression of spermidine/spermine N1-acetyl transferase (SSAT) in human prostate tissues is related to prostate cancer progression and metastasis. Prostate. 2015;75(11):1150–1159.CrossRefPubMedPubMedCentral Huang W, Eickhoff JC, Mehraein-Ghomi F, Church DR, Wilding G, Basu HS. Expression of spermidine/spermine N1-acetyl transferase (SSAT) in human prostate tissues is related to prostate cancer progression and metastasis. Prostate. 2015;75(11):1150–1159.CrossRefPubMedPubMedCentral
14.
go back to reference Hardin H, Guo Z, Shan W, Montemayor-Garcia C, Asioli S, Yu XM, et al. The roles of the epithelial-mesenchymal transition marker PRRX1 and miR-146b-5p in papillary thyroid carcinoma progression. Am J Pathol. 2014;184(8):2342–2354.CrossRefPubMedPubMedCentral Hardin H, Guo Z, Shan W, Montemayor-Garcia C, Asioli S, Yu XM, et al. The roles of the epithelial-mesenchymal transition marker PRRX1 and miR-146b-5p in papillary thyroid carcinoma progression. Am J Pathol. 2014;184(8):2342–2354.CrossRefPubMedPubMedCentral
15.
go back to reference Hardin H, Yu X-M, Harrison AD, Larrain C, Zhang R, Chen J, et al. Generation of Novel Thyroid Cancer Stem-Like Cell Clones Effects of Resveratrol and Valproic Acid. Am J Pathol. 2016;186(6):1662–1673.CrossRefPubMed Hardin H, Yu X-M, Harrison AD, Larrain C, Zhang R, Chen J, et al. Generation of Novel Thyroid Cancer Stem-Like Cell Clones Effects of Resveratrol and Valproic Acid. Am J Pathol. 2016;186(6):1662–1673.CrossRefPubMed
16.
go back to reference Hirata H, Hinoda Y, Shahryari V, Deng G, Nakajima K, Tabatabai ZL, et al. Long noncoding RNA MALAT1 promotes aggressive renal cell carcinoma through Ezh2 and interacts with miR-205. Cancer Res. 2015;75(7):1322–1331.CrossRefPubMed Hirata H, Hinoda Y, Shahryari V, Deng G, Nakajima K, Tabatabai ZL, et al. Long noncoding RNA MALAT1 promotes aggressive renal cell carcinoma through Ezh2 and interacts with miR-205. Cancer Res. 2015;75(7):1322–1331.CrossRefPubMed
17.
go back to reference Zhang Z, Weaver DL, Olsen D, Dekay J, Peng Z, Ashikaga T, et al. Long non-coding RNA chromogenic in situ hybridisation signal pattern correlation with breast tumour pathology. J Clin Pathol. 2016;69(1):76–81.CrossRefPubMed Zhang Z, Weaver DL, Olsen D, Dekay J, Peng Z, Ashikaga T, et al. Long non-coding RNA chromogenic in situ hybridisation signal pattern correlation with breast tumour pathology. J Clin Pathol. 2016;69(1):76–81.CrossRefPubMed
18.
go back to reference Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson, L. D. R, et al. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA Oncol. 2016;2(8):1023–1029. doi: 10.1001/jamaoncol.2016.0386.CrossRefPubMed Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson, L. D. R, et al. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA Oncol. 2016;2(8):1023–1029. doi: 10.​1001/​jamaoncol.​2016.​0386.CrossRefPubMed
19.
go back to reference Al-Khalaf HH, Aboussekhra A. MicroRNA-141 and microRNA-146b-5p inhibit the prometastatic mesenchymal characteristics through the RNA-binding protein AUF1 targeting the transcription factor ZEB1 and the protein kinase AKT. J Biol Chem. 2014;289(45):31433–31447.CrossRefPubMedPubMedCentral Al-Khalaf HH, Aboussekhra A. MicroRNA-141 and microRNA-146b-5p inhibit the prometastatic mesenchymal characteristics through the RNA-binding protein AUF1 targeting the transcription factor ZEB1 and the protein kinase AKT. J Biol Chem. 2014;289(45):31433–31447.CrossRefPubMedPubMedCentral
20.
go back to reference Cancer Genome Atlas Research Network. Integrated Genomic Characterization of Papillary Thyroid Carcinoma. Cell. 2014;159(3):676–690.CrossRef Cancer Genome Atlas Research Network. Integrated Genomic Characterization of Papillary Thyroid Carcinoma. Cell. 2014;159(3):676–690.CrossRef
21.
go back to reference Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 2016;126(3):1052–1066.CrossRefPubMedPubMedCentral Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 2016;126(3):1052–1066.CrossRefPubMedPubMedCentral
22.
go back to reference Braun J, Hoang-Vu C, Dralle H, Hutelmaier S. Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas. Oncogene. 2010;29(29):4237–4244.CrossRefPubMed Braun J, Hoang-Vu C, Dralle H, Hutelmaier S. Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas. Oncogene. 2010;29(29):4237–4244.CrossRefPubMed
23.
go back to reference Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, Ferraro A, et al. Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene. 2007;26(54):7590–7595.CrossRefPubMed Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, Ferraro A, et al. Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene. 2007;26(54):7590–7595.CrossRefPubMed
24.
go back to reference Huang J-K, Ma L, Song W-H, Lu B-Y, Huang Y-B, Dong H-M, et al. MALAT1 promotes the proliferation and invasion of thyroid cancer cells via regulating the expression of IQGAP1. Biomed Pharmacother. 2016;83:1–7.CrossRefPubMed Huang J-K, Ma L, Song W-H, Lu B-Y, Huang Y-B, Dong H-M, et al. MALAT1 promotes the proliferation and invasion of thyroid cancer cells via regulating the expression of IQGAP1. Biomed Pharmacother. 2016;83:1–7.CrossRefPubMed
Metadata
Title
MALAT1 Long Non-coding RNA Expression in Thyroid Tissues: Analysis by In Situ Hybridization and Real-Time PCR
Authors
Ranran Zhang
Heather Hardin
Wei Huang
Jidong Chen
Sofia Asioli
Alberto Righi
Francesca Maletta
Anna Sapino
Ricardo V. Lloyd
Publication date
01-03-2017
Publisher
Springer US
Published in
Endocrine Pathology / Issue 1/2017
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-016-9453-4

Other articles of this Issue 1/2017

Endocrine Pathology 1/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.